COVID-19 Impact on Global Recombinant Vaccines Market By Patient Type (Pediatric and Adult Patients); By Technology (Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines and Toxoid Vaccines) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030
COVID-19 Impact on Global Recombinant Vaccines Market By Patient Type (Pediatric and Adult Patients); By Technology (Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines and Toxoid Vaccines) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030
1. EXECUTIVE SUMMARY
2. RECOMBINANT VACCINES MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MARKET DYNAMICS
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends
6. CORRELATION & REGRESSION ANALYSIS
6.1. Correlation Matrix
6.2. Regression Matrix
7. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
8. RISK ANALYSIS
8.1. Demand Risk Analysis
8.2. Supply Risk Analysis
9. RECOMBINANT VACCINES MARKET ANALYSIS
9.1. Porters Five Forces
9.1.1. Threat of New Entrants
9.1.2. Bargaining Power of Suppliers
9.1.3. Threat of Substitutes
9.1.4. Rivalry
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. RECOMBINANT VACCINES MARKET
10.1. Market Size & forecast, 2019A-2030F
10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11. RECOMBINANT VACCINES MARKET: MARKET SEGMENTATION
11.1. By Regions
11.1.1. North America:(U.S. and Canada)
11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12. RECOMBINANT VACCINES MARKET: MARKET SEGMENTATION
12.1. By technology: Market Share (2020-2030F)
12.1.1. conjugate vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.2. inactivated and subunit vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.3. live attenuated vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.4. recombinant vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.5. toxoid vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2. By patient type : Market Share (2020-2030F)
12.2.1. pediatric, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.2. adult patients, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
13. COMPANY PROFILE
13.1. Johnson and Johnson
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Abiomed
13.3. Emergent Bio Solutions, Inc.
13.4. GlaxoSmithKline
13.5. Sanofi Pasteur SA
13.6. Serum Institute of India Pvt. Ltd
13.7. Mitsubishi Tanabe Pharma Corporation
13.8. Daiichi Sankyo
13.9. Pfizer, Inc.
13.10. Other prominent players
Consultant Recommendation
**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
2. RECOMBINANT VACCINES MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MARKET DYNAMICS
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends
6. CORRELATION & REGRESSION ANALYSIS
6.1. Correlation Matrix
6.2. Regression Matrix
7. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
8. RISK ANALYSIS
8.1. Demand Risk Analysis
8.2. Supply Risk Analysis
9. RECOMBINANT VACCINES MARKET ANALYSIS
9.1. Porters Five Forces
9.1.1. Threat of New Entrants
9.1.2. Bargaining Power of Suppliers
9.1.3. Threat of Substitutes
9.1.4. Rivalry
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. RECOMBINANT VACCINES MARKET
10.1. Market Size & forecast, 2019A-2030F
10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11. RECOMBINANT VACCINES MARKET: MARKET SEGMENTATION
11.1. By Regions
11.1.1. North America:(U.S. and Canada)
11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12. RECOMBINANT VACCINES MARKET: MARKET SEGMENTATION
12.1. By technology: Market Share (2020-2030F)
12.1.1. conjugate vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.2. inactivated and subunit vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.3. live attenuated vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.4. recombinant vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.5. toxoid vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2. By patient type : Market Share (2020-2030F)
12.2.1. pediatric, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.2. adult patients, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
13. COMPANY PROFILE
13.1. Johnson and Johnson
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Abiomed
13.3. Emergent Bio Solutions, Inc.
13.4. GlaxoSmithKline
13.5. Sanofi Pasteur SA
13.6. Serum Institute of India Pvt. Ltd
13.7. Mitsubishi Tanabe Pharma Corporation
13.8. Daiichi Sankyo
13.9. Pfizer, Inc.
13.10. Other prominent players
Consultant Recommendation
**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
